As of June 9th, RudaCure Inc. was recognized for its technological and innovative excellence and selected for the Ministry of SMEs and Startups' Big3 Innovation Sector Startup Package Support Project. The company will receive KRW 300 million annually over three years for R&D and commercialization activities related to GMP finished pharmaceutical production and stability evaluation of RCI001, domestic Phase 1 clinical trials, and FDA Phase 2 clinical trials. Additionally, the company was selected for project support linked to the Ministry of SMEs and Startups, qualifying for a maximum of KRW 13 billion in financial support.